81 institutions hold shares in Matinas BioPharma Holdings Inc. (MTNB), with 7.78M shares held by insiders accounting for 3.81% while institutional investors hold 22.11% of the company’s shares. The shares outstanding are 199.37M, and float is at 184.06M with Short Float at 8.58%. Institutions hold 21.27% of the Float.
The top institutional shareholder in the company is Boxer Capital, LLC with over 11.48 million shares valued at $15.61 million. The investor’s holdings represent 5.62% of the MTNB Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 7.7 million shares valued at $10.47 million to account for 3.77% of the shares outstanding. The other top investors are Vivo Capital, LLC which holds 6.45 million shares representing 3.16% and valued at over $8.77 million, while Blackrock Inc. holds 1.10% of the shares totaling 2.24 million with a market value of $3.05 million.
Matinas BioPharma Holdings Inc. (AMEX: MTNB) is -21.32% lower on its value in year-to-date trading and has touched a low of $0.49 and a high of $2.22 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MTNB stock was last observed hovering at around $1.10 in the last trading session, with the day’s loss setting it -0.03% off its average median price target of $3.00 for the next 12 months. It is also 73.25% off the consensus price target high of $4.00 offered by 5 analysts, but current levels are 46.5% higher than the price target low of $2.00 for the same period.
Currently trading at $1.07, the stock is -5.64% and -15.77% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.56 million and changing -2.73% at the moment leaves the stock 6.33% off its SMA200. MTNB registered 93.25% gain for a year compared to 6-month gain of 39.78%. The firm has a 50-day simple moving average (SMA 50) of $1.2052 and a 200-day simple moving average (SMA200) of $1.1057.
The stock witnessed a 0.00% loss in the last 1 month and extending the period to 3 months gives it a -21.32%, and is -4.46% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.82% over the week and 8.04% over the month.
Matinas BioPharma Holdings Inc. (MTNB) has around 20 employees, a market worth around $208.65M and $0.20M in sales. Distance from 52-week low is 118.37% and -51.80% from its 52-week high.
Matinas BioPharma Holdings Inc. (MTNB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Matinas BioPharma Holdings Inc. (MTNB) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Matinas BioPharma Holdings Inc. is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.03 with sales reaching $20k over the same period.The EPS is expected to grow by 6.30% this year, but quarterly earnings will post 1,077.20% year-over-year.
Matinas BioPharma Holdings Inc. (MTNB) Insider Activity
A total of 1 insider transactions have happened at Matinas BioPharma Holdings Inc. (MTNB) in the last six months, with sales accounting for 0 and purchases happening 1 times. The most recent transaction is an insider purchase by STERN ADAM K, the company’s Director. SEC filings show that STERN ADAM K bought 20,000 shares of the company’s common stock on Aug 21 at a price of $0.83 per share for a total of $16600.0. Following the purchase, the insider now owns 3.3 million shares.
Matinas BioPharma Holdings Inc. (MTNB): Who are the competitors?
Omeros Corporation (OMER) is 49.88% up on the 1-year trading charts. Short interest in the company’s stock has fallen -6.59% from the last report on Feb 11, 2021 to stand at a total of 16.83 million short shares sold with a short interest ratio of 5.27.